Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 2/20 | 0.38 |
| ▸ | GNMT | Q14749 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28226983 | 0.92 | TYMP (0.48) | TYMPADORA1TRDMT1NT5ECARM1 | |
| SCHEMBL4451633 | 0.83 | ADORA3 (0.43) | ADORA1GNMTEGFR | |
| SCHEMBL29521058 | 0.78 | TYMP (0.41) | TYMPADORA1TRDMT1NT5ECARM1 | |
| SCHEMBL3406174 | 0.77 | TYMP (0.42) | TYMP | |
| SCHEMBL16401780 | 0.76 | TYMP (0.45) | TYMPADORA1TRDMT1NT5ECARM1 | |
| SCHEMBL29812366 | 0.76 | ADORA1 (0.44) | TYMPADORA1NT5EEGFR | |
| SCHEMBL3407180 | 0.75 | TYMP (0.40) | TYMPEGFR | |
| SCHEMBL8144937 | 0.75 | TYMP (0.39) | TYMPADORA1TRDMT1NT5ECARM1 | |
| SCHEMBL337874 | 0.75 | ADORA3 (0.45) | ADORA1TRDMT1NNMT | |
| SCHEMBL15752965 | 0.74 | EGFR (0.43) | ADORA1NT5EGNMTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090198047-A1 | 2'-Modified Oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20080032945-A1 | 2'-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-7138517-B2 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20030187240-A1 | 2' -modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030004325-A1 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6005087-A | NUCLEASE RESISTANT OLIGONUCLEOTIDES WHICH ARE USEFUL AS THERAPEUTICS, DIAGNOSTICS, AND RESEARCH REAGENTS FOR VARIOUS VIRAL DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859221-A | HYBRID DNA, RNA; NUCLEASE RESISTANT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |